Search
CorMedix Inc
CRMDAdd to Watchlist
7.190USD
-0.230-3.10%
Close 10-02 16:00（ET）
564.06MMarket Cap
2.96P/E TTM
CorMedix Inc (CRMD) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to CorMedix Inc in the past month.
Buy
2 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
15.333USD+113.26%
CRMD Analyst Recommendation Trends
In the current month, CRMD has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRMD average Analyst price target in the last month is 15.333.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
1
1
1
1
1
1
1
4
4
4
5
6
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
5
5
6
7
7
7
7
CRMD Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Eli Lilly and Co
LLY
10
18
3
1
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, CRMD EPS is projected to reach -0.104 in FY2026Q3, following reported EPS of 0.331 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.82
0.36
0.24
-0.10
-0.13
Actual
0.18
0.49
0.33
--
--
Surprise
-78.23%
+33.12%
+39.20%
--
--
FAQs
What is CorMedix Inc's expected revenue for the next quarter?
CorMedix Inc's expected revenue is 53.23M.
What is CorMedix Inc's price target?
Analysts forecast that CorMedix Inc's price target is USD 15.33, with the highest forecast at USD 19.00 and the lowest forecast at USD 13.00.
How have CorMedix IncCRMD's recent earnings per share performed?
The market expectation was USD 0.33, while CorMedix IncCRMD's earnings per share (EPS) for the previous quarter was USD 0.49. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for CorMedix Inc?
Based on the ratings of CorMedix Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.